Azrin N Abd Rahman1,2, Susan E Tett1, Halim A Abdul Gafor3, Brett C McWhinney4, Christine E Staatz1. 1. School of Pharmacy, University of Queensland, Brisbane, Queensland, Australia. 2. School of Pharmacy, International Islamic University of Malaysia, Kuantan, Pahang, Malaysia. 3. Nephrology Unit, Department of Medicine, Universiti Kebangsaan Malaysia Medical Centre, Cheras, Kuala Lumpur, Malaysia. 4. Department of Chemical Pathology, Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia.
Abstract
AIMS: The aim was to examine relationships between total and unbound mycophenolic acid (MPA) and prednisolone exposure and clinical outcomes in patients with lupus nephritis. METHODS: Six blood samples were drawn pre- and at 1, 2, 4, 6 and 8 h post-dose and total and unbound MPA and prednisolone pre-dose (C0 ), maximum concentration (Cmax ) and area under the concentration-time curve (AUC) were determined using non-compartmental analysis in 25 patients. The analyses evaluated drug exposures in relation to treatment response since starting MPA and drug-related adverse events. RESULTS: Dose-normalized AUC varied 10-, 8-, 7- and 19-fold for total MPA, unbound MPA, total prednisolone and unbound prednisolone, respectively. Median values (95% CI) of total MPA AUC(0,8 h) (21.5 [15.0, 42.0] vs. 11.2 [4.8, 30.0] mg l(-1) h, P= 0.048) and Cmax (11.9 [6.7, 26.3] vs. 6.1 [1.6, 9.2] mg l(-1) , P = 0.016) were significantly higher in responders than non-responders. Anaemia was significantly associated with higher total (37.8 [14.1, 77.5] vs. 18.5 [11.7, 32.7] mg l(-1) h, P = 0.038) and unbound MPA AUC(0,12 h) (751 [214, 830] vs. 227 [151, 389] mg l(-1) h, P = 0.004). Unbound prednisolone AUC(0,24 h) was significantly higher in patients with Cushingoid appearance (unbound: 1372 [1242, 1774] vs. 846 [528, 1049] nmol l(-1) h, P = 0.019) than in those without. Poorer treatment response was observed in patients with lowest tertile exposure to both total MPA and prednisolone as compared with patients with middle and higher tertile exposure (17% vs. 74%, P = 0.023). CONCLUSIONS: This study suggests a potential role for therapeutic drug monitoring in individualizing immunosuppressant therapy in patients with lupus nephritis.
AIMS: The aim was to examine relationships between total and unbound mycophenolic acid (MPA) and prednisolone exposure and clinical outcomes in patients with lupus nephritis. METHODS: Six blood samples were drawn pre- and at 1, 2, 4, 6 and 8 h post-dose and total and unbound MPA and prednisolone pre-dose (C0 ), maximum concentration (Cmax ) and area under the concentration-time curve (AUC) were determined using non-compartmental analysis in 25 patients. The analyses evaluated drug exposures in relation to treatment response since starting MPA and drug-related adverse events. RESULTS: Dose-normalized AUC varied 10-, 8-, 7- and 19-fold for total MPA, unbound MPA, total prednisolone and unbound prednisolone, respectively. Median values (95% CI) of total MPA AUC(0,8 h) (21.5 [15.0, 42.0] vs. 11.2 [4.8, 30.0] mg l(-1) h, P= 0.048) and Cmax (11.9 [6.7, 26.3] vs. 6.1 [1.6, 9.2] mg l(-1) , P = 0.016) were significantly higher in responders than non-responders. Anaemia was significantly associated with higher total (37.8 [14.1, 77.5] vs. 18.5 [11.7, 32.7] mg l(-1) h, P = 0.038) and unbound MPA AUC(0,12 h) (751 [214, 830] vs. 227 [151, 389] mg l(-1) h, P = 0.004). Unbound prednisolone AUC(0,24 h) was significantly higher in patients with Cushingoid appearance (unbound: 1372 [1242, 1774] vs. 846 [528, 1049] nmol l(-1) h, P = 0.019) than in those without. Poorer treatment response was observed in patients with lowest tertile exposure to both total MPA and prednisolone as compared with patients with middle and higher tertile exposure (17% vs. 74%, P = 0.023). CONCLUSIONS: This study suggests a potential role for therapeutic drug monitoring in individualizing immunosuppressant therapy in patients with lupus nephritis.
Authors: Leslie M Shaw; Magdalena Korecka; Raman Venkataramanan; Lee Goldberg; Roy Bloom; Kenneth L Brayman Journal: Am J Transplant Date: 2003-05 Impact factor: 8.086
Authors: Lutz T Weber; Maria Shipkova; Victor W Armstrong; Natalie Wagner; Ekkehard Schütz; Otto Mehls; Lothar B Zimmerhackl; Michael Oellerich; Burkhard Tönshoff Journal: J Am Soc Nephrol Date: 2002-03 Impact factor: 10.121
Authors: Helio Tedesco-Silva; Claudia Rosso Felipe; Alan Slade; Robert L Schmouder; Jose Osmar Medina Pestana Journal: Ther Drug Monit Date: 2012-12 Impact factor: 3.681
Authors: Lorna K Henderson; Philip Masson; Jonathan C Craig; Matthew A Roberts; Robert S Flanc; Giovanni F M Strippoli; Angela C Webster Journal: Am J Kidney Dis Date: 2012-11-22 Impact factor: 8.860
Authors: George K Bertsias; Maria Tektonidou; Zahir Amoura; Martin Aringer; Ingeborg Bajema; Jo H M Berden; John Boletis; Ricard Cervera; Thomas Dörner; Andrea Doria; Franco Ferrario; Jürgen Floege; Frederic A Houssiau; John P A Ioannidis; David A Isenberg; Cees G M Kallenberg; Liz Lightstone; Stephen D Marks; Alberto Martini; Gabriela Moroni; Irmgard Neumann; Manuel Praga; Matthias Schneider; Argyre Starra; Vladimir Tesar; Carlos Vasconcelos; Ronald F van Vollenhoven; Helena Zakharova; Marion Haubitz; Caroline Gordon; David Jayne; Dimitrios T Boumpas Journal: Ann Rheum Dis Date: 2012-07-31 Impact factor: 19.103
Authors: Azrin N Abd Rahman; Susan E Tett; Halim A Abdul Gafor; Brett C McWhinney; Christine E Staatz Journal: Eur J Drug Metab Pharmacokinet Date: 2017-12 Impact factor: 2.441
Authors: Dwarakanathan Ranganathan; Mohd H Abdul-Aziz; George T John; Brett C McWhinney; Robert G Fassett; Helen Healy; Paul Kubler; Aaron Lim; Jeffrey Lipman; Megan Purvey; Matthew Roberts; Reza Reyaldeen; Jacobus Ungerer; Jason A Roberts Journal: Ther Drug Monit Date: 2019-12 Impact factor: 3.681
Authors: Michael Klotsman; Sebastien Coquery; Gayatri Sathyan; Vatsala Naageshwaran; Paddy Shivanand; Amanda J Fairchild; Oliver A Garden; Wayne H Anderson Journal: Front Vet Sci Date: 2021-01-28